%A Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan %T Advances in the amplification of HER2 in metastatic colorectal cancer %0 Journal Article %D 2021 %J Journal of International Oncology %R 10.3760/cma.j.cn371439-20200715-00049 %P 246-249 %V 48 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10987.shtml} %8 2021-04-08 %X

Several studies have shown that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS wild-type metastatic colorectal cancer (mCRC). Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of patients with mCRC.